Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

• Үндсэн зохиолчид: Jinhua Chen (Зохиогч), Linlin Tang (Зохиогч), Wenping Song (Зохиогч), Cuicui Sun (Зохиогч), Wenzhou Zhang (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

IntroductionCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are first-line treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With their increasing clinical use, infection-related adverse events (AEs) associated with CDK4/6 inhibitors have b...